Home infusions of ocrelizumab for multiple sclerosis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and effectiveness of administering ocrelizumab infusions at home for patients with multiple sclerosis. It involves monitoring for infusion reactions and adverse events, comparing these rates to existing studies. Additionally, patient-reported outcomes will be assessed to evaluate changes before and after the infusion. The study aims to provide insights into the feasibility of home-based treatment for MS patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Current active patient of Rocky Mountain MS Center at the time of final study consent.
* Between 18-55 years of age at the time of final study consent.
* Diagnosis of primary progressive or relapsing MS as defined by the 2017 McDonald criteria.19
* Has at minimum completed their first 600 mg dose of ocrelizumab.
* Is physically residing in the Denver metro, Fort Collins or Colorado Springs area at the time of final study consent.
* Has a Patient Determined Disease Steps (PDDS) between 0 to 6.5 20
* Can complete patient reported outcomes developed and validated as English written scales.
* Must be able and willing to give meaningful, informed consent via electronic signature prior to participation in the study, in accordance with local and FDA regulatory requirements.
* Whose treating neurologist at the RMMSC feels that continuing ocrelizumab s medically appropriate based on at the time of final study consent.

Exclusion Criteria:

* Not pregnant, intentions to get pregnant or lactating at the time of final study consent and on the day of infusion.
* Has previously not participated in the SaROD trial at the RMMSC site.
* Any of the following abnormal laboratory results as processed by a University of Colorado Hospital laboratory site and deemed clinically inappropriate to proceed with a home infusion by the treating neurologist at RMMSC.

Where it's running

• Amerita
  Centennial, Colorado, United States Recruiting

Study contacts

• Principal investigator: Timothy L Vollmer, MD — University of Colorado, Denver
• Study coordinator: Brooke Valdez, BS
• Email: brooke.valdez@cuanshutz.edu
• Phone: 303-724-2635

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing Ofatumumab vs Ocrelizumab in Real-World MS Care

  This real-world study tests whether ofatumumab works differently from ocrelizumab for people with multiple sclerosis.

  Recruiting Novartis · East Hanover, New Jersey · NCT07779460

• Ocrelizumab given under the skin after switching from another anti-CD20 therapy

  This study tests a subcutaneous form of ocrelizumab mixed with rHuPH20 in people with relapsing or primary progressive MS who are switching from another anti-CD20 treatment.

  Recruiting at 8 sites Phase 4 Genentech, Inc. · Birmingham, Alabama and 7 other locations · NCT07609719

• Switching to ublituximab for ocrelizumab wearing-off in multiple sclerosis

  This pilot will try switching people with relapsing MS who experience symptom 'wearing off' on ocrelizumab to ublituximab to see if their symptoms improve or return later.

  Recruiting Phase 4 Johns Hopkins University · Baltimore, Maryland · NCT07389590

• Ocrelizumab and GLP‑1 agonists in people with multiple sclerosis

  This project will see if taking GLP‑1 weight‑loss medicines while on ocrelizumab changes progression of disability in adults with multiple sclerosis.

  Recruiting Northwestern University · Chicago, Illinois · NCT07207148

• Investigating the effects of ocrelizumab on neurofilament levels and patient satisfaction in multiple sclerosis

  This study is testing how the medication ocrelizumab affects certain markers in the blood and how satisfied people with multiple sclerosis feel about their treatment after a year.

  Recruiting at 86 sites Hoffmann-La Roche · Aachen and 92 other locations · NCT06780150

• Assessing the impact of Multiple Sclerosis on physical function while providing continued ocrelizumab treatment

  This study is testing how Multiple Sclerosis affects physical function while continuing treatment with the medication ocrelizumab for people who have already been part of related studies.

  Recruiting at 53 sites Phase 3 Hoffmann-La Roche · Pleven and 55 other locations · NCT06675955

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.